NasdaqGS:AMGNBiotechs
Assessing Amgen (AMGN) Valuation After UPLIZNA Approval and New U.S. Drug Pricing Agreements
Amgen (AMGN) just checked two big boxes at once, tightening its partnership with Washington on drug pricing while winning FDA approval for UPLIZNA in generalized myasthenia gravis, and the stock is reacting accordingly.
See our latest analysis for Amgen.
That backdrop of tariff relief and drug price cooperation, combined with the fresh UPLIZNA approval, comes on top of a strong run, with Amgen’s share price up 26.27% year to date and a 5 year total shareholder return of 71.89%, which suggests...